CARISMA Therapeutics Archives · BioBuzz

Loading …

A Unique Talent Pool is Propelling Philly to become a Top Biotech Cluster

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-75x75.png 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-300x300.png" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-300x300.png" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/03/Philly-top-biotech-cluster-75x75.png 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : March 23, 2021March 28, 2021 Published by : Alex Keown

As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.

CARISMA Therapeutics Raises $47 Million to Advance CAR-M Program Into the Clinic

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-75x75.png 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-300x300.png" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-300x300.png" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/01/CARISMA-Therapeutics-featured-img-75x75.png 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : January 12, 2021January 12, 2021 Published by : Alex Keown

Philadelphia-based CARISMA Therapeutics Inc. secured $47 million in a Series B financing round that will be used to advance the development of the company’s novel chimeric antigen receptor macrophages (CAR-M) immunotherapies.